Literature DB >> 17113667

Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients.

Luitpold V R Distel1, Susann Neubauer, Ulrike Keller, Carl N Sprung, Rolf Sauer, Gerhard G Grabenbauer.   

Abstract

BACKGROUND: Radiosensitivity of normal tissue is a crucial factor of radiotherapy (RT)-related side effects. Here, we report the analysis of spontaneous and in vitro irradiation-induced chromosomal aberrations in 256,679 metaphases from 222 different individuals using three-color fluorescence in situ hybridization as a measure of radiosensitivity.
MATERIALS AND METHODS: Samples were categorized into the following 6 groups: (1) healthy individuals, (2) cancer patients prior to radiotherapy, (3) RT-treated cancer patients, (4) individuals heterozygous or (5) homozygous for a mutation in the ataxia telangiectasia mutated (ATM) gene or in the Nijmegen breakage syndrome (NBS1) gene and (6) hypersensitive patients (outliers).
RESULTS: A normal distribution of the number of chromosomal aberrations, measured as breaks per metaphase (B/m), was adopted for all examined groups. The mean value of the control group was 0.40B/m (SD+/-0.07). This value was lower compared to the mean breakage rate from 175 non-exposed (0.50+/-0.12B/m) and pre-exposed (0.50+/-0.16B/m) cancer patients. Nineteen of the metaphase spreads from the analyzed cancer patients had a high number of chromosomal aberrations (1.04+/-0.29B/m) and were designated as a separate hypersensitive subgroup (outliers). The aberration frequency of this group was comparable to those of ATM or NBS1 heterozygotes (0.86+/-0.26B/m). The highest incidence of aberrations was observed in ATM and NBS1 homozygous patients (2.23+/-1.03B/m).
CONCLUSION: The frequency of break events in the analyzed groups resulted in a normal distribution with varying means and broadnesses defining a characteristic sensitivity pattern for each group. In the RT-relevant group of cancer patients, those patients who have cancer, about one-third of the normally distributed samples were determined to be sensitive as defined by the number of induced aberrations higher than the 99% confidence interval of the normal individual's Gaussian distribution. About 5% of these samples were outside of the 99% confidence interval for the RT-relevant group's normal distribution. These outliers with higher chromosomal breakage rates suggest a unique class of hypersensitive individuals that are susceptible to chromosomal damage and may be directly associated with an increased risk to suffer from radiotherapy-related complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113667     DOI: 10.1016/j.radonc.2006.10.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  24 in total

1.  High prevalence of the NBN gene mutation c.657-661del5 in Southeast Germany.

Authors:  M H Maurer; K Hoffmann; K Sperling; R Varon
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

2.  Evaluation of Severe Combined Immunodeficiency and Combined Immunodeficiency Pediatric Patients on the Basis of Cellular Radiosensitivity.

Authors:  Pavel Lobachevsky; Lisa Woodbine; Kuang-Chih Hsiao; Sharon Choo; Chris Fraser; Paul Gray; Jai Smith; Nickala Best; Laura Munforte; Elena Korneeva; Roger F Martin; Penny A Jeggo; Olga A Martin
Journal:  J Mol Diagn       Date:  2015-07-04       Impact factor: 5.568

Review 3.  [Prediction of the reaction of normal tissue and tumor cells to radiotherapy].

Authors:  E Dikomey; J Dahm-Daphi; L Distel
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

4.  H2AX phosphorylation screen of cells from radiosensitive cancer patients reveals a novel DNA double-strand break repair cellular phenotype.

Authors:  R S Vasireddy; C N Sprung; N L Cempaka; M Chao; M J McKay
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

5.  Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy.

Authors:  Ricarda Merten; Markus Hecht; Marlen Haderlein; Luitpold Distel; Rainer Fietkau; Lucie Heinzerling; Sabine Semrau
Journal:  Strahlenther Onkol       Date:  2014-06-26       Impact factor: 3.621

Review 6.  Lethal outcome after pelvic salvage radiotherapy in a patient with prostate cancer due to increased radiosensitivity : Case report and literature review.

Authors:  Antje Fahrig; T Koch; M Lenhart; P Rieckmann; R Fietkau; Luitpold Distel; B Schuster
Journal:  Strahlenther Onkol       Date:  2017-09-08       Impact factor: 3.621

7.  Investigation of Chromosome 1 Aberrations in the Lymphocytes of Prostate Cancer and Benign Prostatic Hyperplasia Patients by Fluorescence in situ Hybridization.

Authors:  Justyna Miszczyk; Mikołaj Przydacz; Michał Zembrzuski; Piotr L Chłosta
Journal:  Cancer Manag Res       Date:  2021-05-31       Impact factor: 3.989

8.  Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil.

Authors:  Tanja Eichkorn; Fabian Schunn; Sebastian Regnery; Rami El Shafie; Juliane Hörner-Rieber; Sebastian Adeberg; Klaus Herfarth; Jürgen Debus; Laila König
Journal:  Strahlenther Onkol       Date:  2021-01-24       Impact factor: 3.621

9.  Chromosomal radiosensitivity and acute radiation side effects after radiotherapy in tumour patients--a follow-up study.

Authors:  Reinhard Huber; Herbert Braselmann; Hans Geinitz; Irene Jaehnert; Adolf Baumgartner; Reinhard Thamm; Markus Figel; Michael Molls; Horst Zitzelsberger
Journal:  Radiat Oncol       Date:  2011-04-07       Impact factor: 3.481

10.  Chromosomal radiosensitivity in head and neck cancer patients: evidence for genetic predisposition?

Authors:  K De Ruyck; V de Gelder; M Van Eijkeren; T Boterberg; W De Neve; A Vral; H Thierens
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.